XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
xtlb · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.23
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.12 | ↓ 5.00% |
1-day model range: $2.07–$2.16. Peak: $2.16 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · XTLB · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2015-05-08 | H.C. Wainwright | Maintains | Buy→Buy |
| 2015-05-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on XTL Biopharmaceuticals Ltd. (XTLB) stock. Of the recent 2 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover XTLB.
Analyst Recommendation Trends
XTLB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast XTLB EPS of $— for the current fiscal year, based on estimates from 0 analysts. The XTLB revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The XTLB stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus XTLB price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The XTLB short-term stock prediction for tomorrow is $2.12 (-5.00%).
XTL Biopharmaceuticals Ltd. trades on NASDAQ under the ticker XTLB. The XTLB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
XTLB forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month XTLB price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.23.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.